A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
Fatty liver disease
FATTY LIVER DISEASE
NewsExposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Recent Posts
- I’m learning how to let go of worry and embrace the moment
- Trial of combo therapy for MASH-related cirrhosis to start this year
- AI model based on imaging, blood tests may help diagnose biliary atresia
- New hepatitis D drug brelovitug marks milestones in late-stage trials
- Study finds ethnic disparities in common liver disease treatment